This product is a MMP9 expressing oncolytic herpes simplex virus, which is based on HSV-1 with ICP27 deleted. ICP27 is highly cytotoxic probably due to its secondary role of preventing the splicing of pre-mRNAs in favour of translation from the mainly unspliced hepes RNAs. Deletion of ICP27 might produce a safer and less cytotoxic system when combined with other oncolytic-rendered modifications. This product can be used in oncolytic virotherapy research and further recombinant HSV construction.
Specifications
Family
Herpesviridae
Species
Herpes simplex virus
Serotype
Herpes simplex virus 1
Backbone
HSV-1 (ΔICP27)
Backbone Background
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as human herpesvirus 1 and 2 (HHV-1 and HHV-2), are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans. Modified Herpes simplex virus is considered as a potential therapy for cancer and has been extensively clinically tested to assess its oncolytic ability.
Matrix metallopeptidase 9 (MMP-9), also known as 92 kDa type IV collagenase, 92 kDa gelatinase or gelatinase B (GELB), is a matrixin, a class of enzymes that belong to the zinc-metalloproteinases family involved in the degradation of the extracellular matrix. In humans the MMP9 gene encodes for a signal peptide, a propeptide, a catalytic domain with inserted three repeats of fibronectin type II domain followed by a C-terminal hemopexin-like domain.
Customer Reviews and Q&As
There are currently no customer reviews or questions for MMP9-expressing Oncolytic Herpes Simplex Virus 1 (ΔICP27), hTERT-MMP9 (CyOV-0077XY). Click the button below to contact us or submit your feedback about this product.
All products and services are for Research Use Only. Not For Clinical Use.